ArticleDiabetes, obesity & metabolism2011
Treatment intensification in patients with type 2 diabetes who failed metformin monotherapy.
Article in Diabetes, obesity & metabolism, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05535322 (Real-world Evaluation of GLP-1 Receptor Agonists), which is not on this map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Real-world Evaluation of GLP-1 Receptor Agonists (GLP-1RA) on Efficacy and Persistence, Adherence and Therapeutic Inertia Among Type 2 Diabetes Adults With Obesity in the Department of Health of Valencia Clínico-Malvarrosa
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Effect of DPP-IV Inhibitors on Glycemic Variability in Patients with T2DM: A Systematic Review and Meta-Analysis.Scientific reports · 2019Pooled it
- Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review.Diabetes, obesity & metabolism · 2018 · on this mapPooled it
- Evaluating Therapeutic Inertia in Two Telehealth Interventions for Type 2 Diabetes: Secondary Analyses of a Randomized Trial.Telemedicine journal and e-health : the official journal of the American Telemedicine Association · 2024Trial
- An observational study of clinical inertia among patients with type 2 diabetes mellitus in a tertiary care hospital.Archives of medical science : AMS · 2026Article
- Wait Times for Scheduling Appointments for Prevention of Macrovascular and Microvascular Complications of Diabetes: Cross-Sectional Descriptive Study.Journal of medical Internet research · 2024Article
- Therapeutic Inertia in the Management of Type 2 Diabetes: A Narrative Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Review
- Type 2 diabetes progression in an adult Ugandan population with new-onset diabetes: an observational prospective study.BMC primary care · 2023Observational
- Trends in Timing of and Glycemia at Initiation of Second-line Type 2 Diabetes Treatment in U.S. Adults.Diabetes care · 2022Article
- Evaluating the Evidence behind the Novel Strategy of Early Combination from Vision to Implementation.Diabetes & metabolism journal · 2020Review
- Addressing Therapeutic Inertia in 2020 and Beyond: A 3-Year Initiative of the American Diabetes Association.Clinical diabetes : a publication of the American Diabetes Association · 2020Article
- The impact of phenotype, ethnicity and genotype on progression of type 2 diabetes mellitus.Endocrinology, diabetes & metabolism · 2020Review
- Why Are We Stuck? Therapeutic Inertia in Diabetes Education.Diabetes spectrum : a publication of the American Diabetes Association · 2020Article
- Clinical inertia in type 2 diabetes management in a middle-income country: A retrospective cohort study.PloS one · 2020Article
- Clinical inertia is the enemy of therapeutic success in the management of diabetes and its complications: a narrative literature review.Diabetology & metabolic syndrome · 2020Review
- Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine.Advances in therapy · 2019Review
- Performance of a computable phenotype for identification of patients with diabetes within PCORnet: The Patient-Centered Clinical Research Network.Pharmacoepidemiology and drug safety · 2019Article
- Factors Associated with Diabetes-Related Clinical Inertia in a Managed Care Population and Its Effect on Hemoglobin A1c Goal Attainment: A Claims-Based Analysis.Journal of managed care & specialty pharmacy · 2019Article
- Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia.Therapeutic advances in endocrinology and metabolism · 2019Review
- Efficacy and Safety of Initial Combination Therapy in Treatment-Naïve Type 2 Diabetes Patients: A Systematic Review and Meta-analysis.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2018Article
- Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate the time to and factors associated with treatment intensification in patients with type 2 diabetes who failed metformin monotherapy.
methodsIn a retrospective analysis using a large US electronic medical record database, eligible patients included those with type 2 diabetes and an HbA(1c) of ≥7.0% or at least two fasting blood glucose levels of ≥126 mg/dl while on metformin monotherapy for at least 6 months within the period of 1 January 1997 to 31 December 2008. Time to treatment intensification was calculated as the time between index date (date on which HbA(1c) ≥ 7% after metformin monotherapy for at least 6 months) and first prescription for additional antihyperglycaemic agent during follow-up period. All patients were required to have data for at least 12 months prior to and following the index date. A Cox proportional hazards model was employed to determine patient baseline characteristics associated with time to treatment intensification.
resultsOf the 12 566 patients identified, mean age at index date was 63 years and 51% were female. Mean index HbA(1c) was 8.0% overall, with 66, 19 and 15% of patients having an index HbA(1c) of 7 to <8%, 8 to <9% and ≥9%, respectively. Median time to treatment intensification was 14.0 months overall and 19.0, 8.7 and 4.5 months for patients with index HbA(1c) of 7 to <8%, 8 to <9% and ≥9%, respectively. Factors associated with treatment intensification included higher index HbA(1c) , younger age, higher Charlson co-morbidity index, metformin daily dose ≥ 1500 mg and later index date (all p < 0.05).
conclusionsIn US clinical practice, median time to receive additional antihyperglycaemic medication is more than 1 year for patients with type 2 diabetes who failed metformin monotherapy.
Indexed as
Identifiers
21457427What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.